GlaxoSmithKline Pharma Publishes Corrigendum to Postal Ballot Notice
GlaxoSmithKline Pharmaceuticals Limited issued a corrigendum to its postal ballot notice dated August 3, 2026. The correction pertains to a typographical error in Mr. Akshikar's basic salary, which should be ₹24,00,000/- per month. The corrigendum is available on the company and stock exchange websites.
The announcement is a minor correction of a typographical error in a postal ballot notice and is unlikely to have any significant impact on the company's business operations or stock performance.
The announcement is a routine regulatory filing correcting a typographical error in a previous notice and does not contain information that would positively or negatively impact the company's stock.
GlaxoSmithKline Pharmaceuticals Limited has issued a corrigendum to its postal ballot notice dated August 3, 2026. This corrigendum, dispatched on September 1, 2026, to members whose names appeared in the Register of Members as of August 7, 2026, addresses a typographical error in the explanatory statement.
Specifically, the error was in the basic salary figure of Mr. Akshikar. The correct basic salary should be read as ₹24,00,000/- per month, not ₹24,00,0000/- per month. The corrigendum forms an integral part of the original notice and must be read in conjunction with it. All other contents of the notice and the explanatory statement remain unchanged.
The corrigendum is available on the company's website (www.gsk-india.com/Investors/shareholders-information/postal-ballot), the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com), and KFin Technologies Limited's e-voting website (https://evoting.kfintech.com). This announcement is made pursuant to Regulation 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015.
A plain-language summary of a public exchange filing by GlaxoSmithKline Pharmaceuticals Limited. Read the original for the full detail.